EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

Guideline- Versus Non-Guideline-Based Neoadjuvant Management of Clinical T4 Rectal Cancer

Xi Chen, Xinyu Xie, Xiaodong Wang iD, Mingtian Wei, Zhigui Li, Li Li

Current Oncology · 21.10.2023 · 30 (10) · 9346-9356

DOI: 10.3390/curroncol30100676 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Current Oncology, online erschienen am 21.10.2023. Verfasst von Xi Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastrointestinal Surgery, Department of General Surgery, West China Hospital of Sichuan University, Chengdu 610041, China. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Rectal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the West China Hospital of Sichuan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

(1)

Background

Practice guidelines recommend neoadjuvant treatment for clinical T4 rectal cancer. The primary objective of this retrospective study was to assess whether compliance with guidelines correlates with patient outcomes. Secondarily, we evaluated predictors of adherence to guidelines and mortality. (2)

Methods

A total of 397 qualified rectal cancer (RC) patients from 2017 to 2020 at West China Hospital of Sichuan University were included. Patients were divided into two groups depending on adherence to neoadjuvant treatment guidelines. The main endpoints were overall survival (OS) and disease special survival (DSS). We analyzed factors associated with guideline adherence and mortality. (3)

Results

Compliance with guidelines was only 39.55%. Patients’ neoadjuvant therapy treated not according to the guidelines for clinical T4 RC was not associated with an overall survival (95.7% vs. 88.9%) and disease special survival (96.3% vs. 91.1%) benefit. Patients were more likely to get recommended therapy with positive patient compliance. Staging Ⅲ, medium/high differentiation and objective compliance were associated with increased risk of mortality. (4)

Conclusions

Guideline adherence for clinical T4 RC in our system is low. Compliance with the relevant guidelines for neoadjuvant therapy seems not to lead to better overall survival for patients with clinical T4 RC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyRectal NeoplasmsHumansRetrospective StudiesTreatment OutcomeNeoplasm Staging

Stichwörter der Autor:innen

guidelineneoadjuvant therapyrectal cancer

Autor:innen und Institutionen

  • Division of Gastrointestinal Surgery, Department of General Surgery, West China Hospital of Sichuan University, Chengdu 610041, China.
  • West China School of Medicine, West China Hospital of Sichuan University, Chengdu 610041, China.
  • Colorectal Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, China.

ORCID-Profile: Xiaodong Wang

Förderung

  • the West China Hospital of Sichuan University

Zitieren

APA

Chen, X., Xie, X., Wang, X., Wei, M., Li, Z., & Li, L. (2023). Guideline- Versus Non-Guideline-Based Neoadjuvant Management of Clinical T4 Rectal Cancer. Current Oncology, 30(10), 9346-9356. https://doi.org/10.3390/curroncol30100676

Vancouver

Chen X, Xie X, Wang X, Wei M, Li Z, Li L. Guideline- Versus Non-Guideline-Based Neoadjuvant Management of Clinical T4 Rectal Cancer. Current Oncology. 2023;30(10):9346-9356. doi:10.3390/curroncol30100676

BibTeX
@article{Chen2023,
  author = {Chen, Xi and Xie, Xinyu and Wang, Xiaodong and Wei, Mingtian and Li, Zhigui and Li, Li},
  title = {Guideline- Versus Non-Guideline-Based Neoadjuvant Management of Clinical T4 Rectal Cancer},
  journal = {Current Oncology},
  year = {2023},
  volume = {30},
  number = {10},
  pages = {9346--9356},
  doi = {10.3390/curroncol30100676}
}
Kostenlos starten →